NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
35 hedge funds and large institutions have $1.13M invested in NeuBase Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 12 closing their positions.
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
13% less funds holding
Funds holding: 40 → 35 (-5)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
67% less call options, than puts
Call options by funds: $11K | Put options by funds: $33K
89% less capital invested
Capital invested by funds: $10.7M → $1.13M (-$9.59M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$110K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$48.2K |
| 3 |
VF
Virtu Financial
New York
|
+$36.4K |
| 4 |
Renaissance Technologies
New York
|
+$34.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$23.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell & Co
New York
|
-$915K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$218K |
| 3 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$161K |
| 4 |
Neuberger Berman Group
New York
|
-$86K |
| 5 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$74K |
NBSE Hedge Fund Activity: Q1 2018 in Review
35 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2018, worth a combined $1.13M — down 89% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NBSE and 7 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $110K. The largest seller was Cannell & Co, exiting entirely with an estimated $915K sold.
- 35 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2018, down from 40 in Q4 2017.
- Funds reported $1.13M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2018, down 89% quarter-over-quarter.
- 7 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2018 and 12 closed out, a net change of -5 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2018 was Vanguard Group, an estimated $110K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2018 was Cannell & Co, an estimated $915K sold.
Based on aggregated 13F filings for Q1 2018.